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Membranous nephropathy (MN) is a glomerular disease commonly found in transplanted kidneys. The
natural history of MN post-transplant is unpredictable and spontaneous remission is uncommon. Dia-
betic nephropathy (DN) is also commonly seen in patients with prolonged new onset diabetes mellitus
after transplant (NODAT). However, there have been no previous reports of co-existing MN and DN in
transplanted kidneys. We herein report a case of a 53-year-old male with early post-transplant protei-
nuria and microscopic hematuria due to MN with subsequent clinical spontaneous remission. Due to the
early onset of disease after transplant and presence of serum anti-phospholipase A2 receptor (anti-
PLA2R) antibody, the evidence suggests primary recurrent MN in this patient. He was then diagnosed
with NODAT, with fair glycemic control with oral hypoglycemic agents. Sixteen years after remission, he
developed recurrent proteinuria and progressive impairment of renal function. The allograft biopsy re-
vealed both MN and DN. Both diseases may have contributed to the development of glomerular pa-
thology in this patient.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Membranous nephropathy (MN) is a common cause of ne-
phrotic syndrome in adults and is one of the most frequent glo-
merular diseases found in the post-transplant period [1] leading to
poor allograft survival [2]. New onset diabetes mellitus after
transplant (NODAT) has been reported to occur in 4–25% of renal
transplant recipients [3–8] and may lead to diabetic nephropathy
(DN), which results in lower allograft and patient survival [4,5,9–
15]. However, there have been no previous reports of co-existing
of MN and DN in transplanted kidneys. Here, we report a case of
co-existing post-transplant MN with DN as a complication of
NODAT.2. Case report
A 53-year-old Thai male with end-stage renal disease (ESRD)
due to hypertensive nephropathy received an HLA-identical allo-
graft renal transplant from his brother in February 1997. He had noInc. This is an open access article u
tachuvesiri).prior history of diabetes mellitus (DM) but his mother was a dia-
betic. Induction treatment with methylprednisolone 1000 mg,
500 mg, and 250 mg was given on days 0, 1 and 2, respectively.
The maintenance immunosuppressive regimen consisted of cy-
closporine A 350 mg/day and prednisolone 20 mg/day. His post-
operative period was uneventful and allograft function was
excellent.
Within four months after the transplant, his serum creatinine
level rose from 1.2 mg/dL to 3.3 mg/dL. Allograft biopsy was per-
formed and showed no signs of graft rejection. Cyclosporin-in-
duced nephrotoxicity was diagnosed since the highest cyclosporin
trough level reported was 414 ng/ml (Fig. 1A). After the dosage of
cyclosporin was lowered, the serum creatinine level decreased to
1.6 mg/dL (Fig. 1B).
In 1998, he developed DM, which was controlled with glipizide
5 mg/day and sitagliptin 100 mg/day resulting in fair glycaemic
control with HbA1c levels between 6.3% and 8.1% (Fig. 1C). His
systolic blood pressure varied between 130 and 160 mmHg and
diastolic blood pressure varied between 80 and 110 mmHg
(Fig. 1D).
In 1999, urinalysis during follow up revealed proteinuria with a
urine protein of 2.8 g/day, RBC 5–10/HPF with no cellular casts.
Allograft biopsy revealed thickening of the glomerular capillary
walls in all glomeruli. A diagnosis of MN and hyalinender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. A Cyclosporine A level in the post-transplant period. B Serum creatinine level in the post-transplant period. C FBS and HbA1c level in the post-transplant period. D
Blood pressure (BP) level in the post-transplant period. E Urine Protein Dipstick in the post-transplant period.
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nuria with poor response. He had spontaneous clinical remission
after 4 years of treatment (Fig. 1E).
In 2014, he presented with pitting edema in both legs, and
positive dipstick proteinuria. The UPCR was 1.85 g/g, serum albu-
min of 3.29 g/dL, cholesterol of 185 mg/dL and anti-phospholipase
A2 receptor (anti-PLA2R) was detected in the serum. Renal ultra-
sonography revealed a normal appearance of the renal allograft.
HBsAg, anti-HBs, Anti-HCV and anti-HIV were negative. Allograft
biopsy was performed and showed thickened capillary wall and
expanded mesangial matrix in the glomeruli (Fig. 2A), weak linear
IgG deposition on immunoﬂuorescence (Fig. 2C) and thickened
basement membrane (510–614 nm.) on electron microscopy
(Fig. 2D), compatible with diabetic nephropathy, class 2 [16]. In
addition, granular deposits of IgG along the capillary wall (Fig. 2C)
corresponded with spikes on light microscopy and foci of electron
lucent and dense deposits in subepithelium and intramembrane
(Fig. 2D), all features of membranous nephropathy. C4d was ne-
gative in the peritubular capillaries but positive in glomerular
capillaries (Fig. 2B).
Supportive treatment with ACEI and statin were given. The
patient still had persistent proteinuria of 5 g/day and a serum
creatinine level of 2.2 mg/dL (CKD-EPI eGFR 33 ml/min per
1.73 m2) at the last follow up. In addition, there was no clinical
evidence of diabetes mellitus or kidney disease in the sibling do-
nor post-transplantation after 17 years follow up.3. Discussion
We present this case of co-existing MN and DN in a transplant
patient. One year after transplantation he developed NODAT, the
most common complication in renal transplant patients [5,10] and
has been reported to occur in 4–25% of recipients [3–8]. The cause
of NODAT in this patient was thought to be due to the side effects
of the immunosuppressive agents including cyclosporine A and
prednisolone [5,10,15,17–24] combined with a family history of
DM. In previous studies, the familial history of DM along with race,
age, genetic background, previous glucose intolerance, obesity,
hepatitis C virus, and cytomegalovirus infection were risk factors
of NODAT [25,26]. The patient's NODAT was fairly controlled with
oral hypoglycemic agents.
Two years after transplantation, he developed proteinuria and
microscopic hematuria. Allograft biopsy revealed thickening of the
glomerular capillary walls in all glomeruli, consistent with the
histopathological features of MN [27]. From previous reports, re-
current MN occurred earlier than de novo MN (15.58719.13 vs
49.27732.71 months), our patient was therefore considered as
recurrent MN, which has been reported to occur in 2.5% of
transplanted patients [28]. Such a signiﬁcant difference suggests
that different mechanisms are involved in the physiopathology of
these diseases. For de novo MN, HCV and donor-speciﬁc antibody
seem to be the important etiologic factors [28,29]. Since no known
etiologies of MN including viral infection, malignancy,
Fig. 2. Histopathologic ﬁndings. The glomerulus shows thickened capillary wall and expand mesangial matrix (A, PAS 400 ). The immunoperoxidase staining for C4d
demonstrate positive reactivity in glomerular capillary wall and negative reactivity in peritubular capillaries (B, 400 ). The immunoﬂuorescence staining for IgG shows
granular pattern on glomerular basement membrane and weak linear pattern on glomerular basement membrane and tubular basement membrane (C, FITC 400 ). The
ultrastructure of the glomerulus shows thickened basement membrane and electron lucent/dense deposits in subepithelium (D, 6000 ).
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date, we believe he has idiopathic MN. In addition, the allograft
biopsy also revealed hyaline arteriosclerosis, which can be found
in hypertensive nephropathy, calcineurin inhibitor nephrotoxicity,
or DN. Enalapril was given to control proteinuria but without re-
sponse. He had spontaneous clinical remission after 4 years of
treatment. Spontaneous remission of idiopathic MN has been ob-
served among transplant patients and is a well-known feature
[29–31].
Seventeen years after transplant, he presented with leg edema
and recurrent proteinuria. The differential diagnoses were re-
current MN, DN, and transplant glomerulopathy. Allograft biopsy
revealed histopathological features of both MN and DN. The he-
patitis and HIV viral studies were negative except for anti-phos-
pholipase A2 receptor (PLA2R) antibody which was detected in the
serum. Anti-PLA2R antibody is a biomarker that can be used to
differentiate between idiopathic and secondary MN [32–35].
Therefore, it was more likely that the patient had idiopathic re-
current MN. In this patient, DN was identiﬁed 16 years after the
diagnosis of NODAT. In previous studies, NODAT has been reported
to cause DN approximately 5.9 years after transplantation [36].
Even though MN and DN are common in the post-transplant
period, co-existence of MN and DN has yet to be reported. Post-
transplant spontaneous remission of MN can be observed, but MN
may lead to poor allograft survival [2]. Long standing DM after
kidney-transplant causes signiﬁcant pathological injury to the al-
lograft, resulting in lowered allograft and patient survival [4,5,9–
15]. The United States Renal Data System (USRDS) has clearly
stated the relationship between NODAT and a 63% increase in graft
failure and an 85% increase in mortality [37]. Individually, MN and
DN have a negative impact on allograft survival. We believe thathaving both MN and DN may contribute to an evenworse outcome
than having either disease alone.
In native kidneys, all patients with MN should receive best
supportive care, including treatment with ACEI/ARB, lipid low-
ering agents, and adequate control of blood pressure [38]. The use
of immunosuppressive therapy should be considered on an in-
dividual basis [39]. In this case, supportive care and im-
munosuppressive therapy were already given. It is well known
that immunosuppressors are needed to avoid graft rejection, but
their beneﬁcial effects on post-transplant MN have not yet been
validated [31].References
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